As part of the NICE’s single technology appraisal process, this assessment critically reviewed the manufacturer’s submission related to the evidence for the clinical and cost-effectiveness of Dapagliflozin in combination with other glucose-lowering therapies, including insulin, for adults with type 2 diabetes.
Dapagliflozin proved to be a clinically effective drug, which improved glycaemic control and provided benefits in terms of weight changes and systolic blood pressure. There was, however, a lack of direct trials against the main comparators (DPP-4 inhibitors) and long-term data. There was also no robust evidence on the effects of Dapagliflozin in triple therapy.
Dapagliflozin in a dual therapy regimen has been recommended by NICE as an option for treating type 2 diabetes. For further information see: http://guidance.nice.org.uk/TA288.
Miriam Brazzelli; email@example.com